Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. is registering 4,836,245 shares of common stock for resale by existing investors, largely tied to recently issued pre-funded and series warrants plus placement agent warrants. The company itself will not receive proceeds from these resale transactions.
Amesite may receive up to about $5.38 million if all related warrants are exercised for cash. The filing highlights a strategic pivot to AI-powered NurseMagic™ solutions for post-acute healthcare, but also discloses continued operating losses, Nasdaq listing pressures, and substantial doubt about its ability to continue as a going concern without additional financing.
Amesite Inc. Schedule 13G reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the "Reporting Persons") each may be deemed to beneficially own 293,575 shares of Common Stock, representing 4.99% of the class as of the close of business on May 1, 2026. The filing states that immediately following the execution of a Securities Purchase Agreement on April 27, 2026, the Reporting Persons may have been deemed to beneficially own 348,433 shares (approximately 7.1%) based on 4,572,713 shares outstanding as of April 24, 2026 plus the shares to be issued at closing. The disclosure explains multiple warrants to be issued to Intracoastal with exercisability limits and "blocker provision" restrictions that cap exercise to avoid exceeding 4.99%.
Amesite Inc. entered into multiple financing agreements combining a registered direct offering, a PIPE and an insider-led private placement to raise new equity capital and issue warrants. The company agreed to sell 696,866 registered shares of common stock at $1.435 per share, plus pre-funded warrants and common warrants in a concurrent private placement, and an additional 418,118 shares and matching warrants to officers and directors at $1.435 per share.
The transactions are expected to generate aggregate gross proceeds of about $2 million from the registered direct and PIPE, and about $600,000 from the insider-led private placement, before fees and expenses. If all investor and insider warrants are exercised for cash, Amesite could receive approximately $4 million in additional gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes.
Amesite states that, after these financings, it believes stockholders’ equity will exceed $2.5 million, which is the minimum required to regain compliance with Nasdaq’s stockholders’ equity listing standard, although Nasdaq will continue to monitor ongoing compliance and delisting remains a risk if equity falls below that threshold again.
Amesite Inc. is offering 696,866 shares of common stock at an offering price of $1.435 per share pursuant to this prospectus supplement, with expected gross proceeds of approximately $1.0 million. The offering is being conducted with H.C. Wainwright & Co. as exclusive placement agent and closes subject to customary conditions.
Concurrently, Amesite is conducting a private placement of Pre-Funded Warrants and two series of unregistered common stock warrants (Series A-1 and Series A-2) to the purchasers under the Securities Purchase Agreement dated April 27, 2026. Certain directors (including the CEO) are participating in the Private Placement on the same economic terms, and the Audit Committee and Board approved those related-party investments.
Amesite Inc. furnished updated shareholder presentation materials outlining progress of its AI-driven NurseMagic platform and broader business. The update highlights large non-acute care markets across home care, home health, hospice, senior living and skilled nursing, and describes disruptive documentation and EMR pricing starting around $1 per patient per month.
The materials note prior revenue momentum, including earlier periods with 240% and 63% revenue growth and Q2 2026 revenues of $108,050, along with a mix of B2C and B2B customers. Amesite also emphasizes having zero corporate debt, several months of operating cash coverage, growing social media reach for NurseMagic, and a sales pipeline of multi-site healthcare organizations.
Amesite Inc. is registering 2,777,778 shares of common stock with accompanying warrants, plus related pre-funded warrants and underlying shares, in a primary public offering. The assumed combined price is $1.80 per share and warrant, with estimated net proceeds of about $4.47 million for working capital and general corporate purposes.
Each accompanying warrant has a $1.80 exercise price, is immediately exercisable, and expires five years after issuance. Investors that would exceed 4.99% (or 9.99% at their election) ownership may receive pre-funded warrants with a $0.001 exercise price instead of common stock. Shares outstanding are expected to increase from 4,572,713 to 7,350,491, excluding the underwriters’ 416,667-share over-allotment option.
The company highlights substantial risks, including recurring net losses, substantial doubt about its ability to continue as a going concern, intense competition in AI healthcare, heavy regulatory and cybersecurity demands, and the risk of Nasdaq delisting if it cannot regain and maintain stockholders’ equity compliance.
OMENN GILBERT S reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, received a grant of 6,522 restricted stock units on March 31, 2026. Each unit represents one share of Amesite common stock or its cash equivalent, awarded in lieu of cash director fees based on the quarter-end closing share price. The deferred stock units or cash equivalent will be delivered after he leaves the board or upon an earlier change in control. Following this award, the trust’s indirect holdings reported in this line total 74,783 shares.
Brewer Barbie reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Barbie Brewer received a grant of 7,541 restricted stock units. These RSUs were awarded as deferred stock units in lieu of cash fees for her board service, with the number of units based on the closing share price on the last day of the quarter.
Each RSU represents the right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after she completes service on the board or upon an earlier change in control. Following this grant, she holds 30,322 shares or equivalents directly.
Parmer George reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director George Parmer received a grant of 6,522 restricted stock units. These RSUs were issued as deferred stock units in lieu of cash compensation for his board service, with the number of units based on Amesite’s closing share price on the last day of the quarter.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Parmer’s board service ends or upon an earlier change in control. Following this award, he holds 67,887 shares or share-equivalent units directly.